Supratek Pharma Inc. | Date: 2013-03-11
The present invention is directed to pharmaceutical compositions comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent having a charge opposite to that of the cyclopolysaccharide. Such composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. Such compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.
Supratek Pharma Inc. | Date: 1998-08-11
block co-polymer based drug delivery pharmaceuticals used to deliver small molecules, proteins, peptides, oligonucleotides, ribosomes, antisense, plasmid-DNA, and genes to specific sites in the human body. Pharmaceutical product research and development.
Semov A.,Supratek Pharma Inc. |
Iourtchenco L.,Supratek Pharma Inc. |
Lin Fang L.,Supratek Pharma Inc. |
Shengmin L.,Supratek Pharma Inc. |
And 5 more authors.
Biochemical and Biophysical Research Communications | Year: 2012
Epidemiologic studies repeatedly have shown chemopreventive effects of cruciferous vegetables. Indole-3-carbinol (I3C) and its metabolite diindolylmethane (DIM) were identified in these plants as active ingredients and theirs anti-tumor activities were confirmed in multiple in vitro and in vivo experiments. Here, we demonstrate that DIM is a selective and potent inhibitor of cancer stem cells (CSCs). In several cancer cell lines, DIM inhibited tumor sphere formation at the concentrations 30-300 times lower than concentrations required for growth inhibition of parental cells cultured as adherent culture. We also found that treatment with DIM overcomes chemoresistance of CSCs to cytotoxics, such as paclitaxel, doxorubicin, and SN-38. Pre-treatment of tumor spheres with DIM before implantation to mice significantly retarded the growth of primary tumors compared to tumors formed by untreated tumor spheres. The concentrations of DIM required to suppress CSCs formation are in the close range to those achievable in human plasma after oral dosing of the compound. Therefore, DIM can potentially be used in cancer patients, either alone, or in combinations with existing drugs. © 2012 Elsevier Inc. Source
Kiselev V.,RAS Research Center Kurchatov Institute |
Klinskiy E.,Supratek Pharma Inc. |
Lee S.,Supratek Pharma Inc. |
Muyzhnek E.,MiraxBiopharma |
And 2 more authors.
Journal of Nanomedicine and Nanotechnology | Year: 2013
At the present, a high potential of 3,3'-diindolylmethane (DIM) as a new preventive and therapeutic agent in oncology is well established, due to its ability to target multiple components of cancer cell cycle regulation, survival and progression. However, a very low bioavailability of DIM remains the major challenge for its efficient development as novel medicine. In this work, we have developed a polymer based nano-formulation comprising a non-ionic block copolymer, Pluronic F127 that increases oral bioavailability of DIM by almost one order of magnitude, as compared to the presently marketed products such as crystalline DIM and BioResponse DIM. The pharmacokinetic parameters established in the present study revealed that AUC and Cmax of the new formulation dosed at 60 mg/kg were 7.06 ± 0.93 μg · h/mL, and 3.08 ± 0.17 μg/mL, while in the case of crystalline DIM dosed at the same dose AUC and Cmax were 0.97 ± 0.08 μg · h/mL, and 0.18 ± 0.02 μg/mL. BioResponce DIM showed AUC and Cmax of 1.05 ± 0.05 μg · h/mL, and 0.22 ± 0.02 μg/mL, respectively. © 2013 Kiselev V, et al. Source
Valle J.W.,Christie Hospital NHS Trust |
Valle J.W.,University of Manchester |
Armstrong A.,Christie Hospital NHS Trust |
Newman C.,Supratek Pharma Inc. |
And 8 more authors.
Investigational New Drugs | Year: 2011
Purpose:To evaluate the antitumor activity of SP1049C, a novel P-glycoprotein targeting micellar formulation of doxorubicin, consisting of doxorubicin and two non-ionic block copolymers (pluronics), in patients with advanced adenocarcinoma of the esophagus and gastro-esophageal junction (GEJ). Patients and Methods: Patients with metastatic or locally advanced unresectable adenocar-cinoma of the esophagus or GEJ who had not previously received systemic chemotherapy and had measurable disease were treated with SP1049C 75 mg/m 2 (doxorubicin equivalents) as a brief intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was the objective response rate in patients who had received a least one course of SP1049C and had undergone tumor assessment, whereas, secondary endpoints included the objective response rate, progression-free survival (PFS), overall survival, and safety in the intent-to-treat (ITT) population. A review of scans was also conducted post-hoc by a blinded panel of radiologists. Results: Twenty-one patients, of which 19 were evaluable for response, were treated with at least one dose of SP1049C. Nine patients had a partial response (PR) and eight patients had either a minor response or stable disease as their best response. The objective response rate was 47% (95% CI:24.4-71) in the evaluable patient population, whereas the objective response rate was 43% (95% CI:21.8-65.9) in the ITT population. The post-hoc radiological review confirmed that all nine responders had a PR; seven of the nine had a PR that was confirmed by a subsequent scan, whilst two patients had unconfirmed PRs. The median overall survival and PFS were 10.0 months (95%CI:4.8-11.2) and 6.6 months (95% CI:4.5-7.6), respectively. Neutropenia was the principal toxicity of SP1049C. Four patients developed an absolute percentage decrement of at least 15% in their left ventricular ejection fraction, none of which decreased to below 45% nor were symptomatic. Conclusion: SP1049C has a notable single-agent activity in patients with adenocarcinoma of the esophagus and GEJ, as well as an acceptable safety profile. These results, in addition to the results of preclinical studies demonstrating superior antitumor activity of SP1049C compared with doxorubicin in a standard formulation, indicate that further evaluations of SP1049C alone or combined with other relevant therapeutics in this disease setting are warranted. © Springer Science+Business Media, LLC 2010. Source